• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

and co-mutations in resectable non-small cell lung cancer: enduring prognostic value and impaired immunotherapy response.

作者信息

Sisca Luisana, Cascetta Priscilla, Aijaz Ayesha, Catania Chiara, Facchinetti Francesco, Naqash Abdul Rafeh, Ricciuti Biagio, Cortellini Alessio

机构信息

Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy.

Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.

出版信息

Transl Lung Cancer Res. 2025 Jul 31;14(7):2374-2382. doi: 10.21037/tlcr-2025-463. Epub 2025 Jul 22.

DOI:10.21037/tlcr-2025-463
PMID:40799447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12337074/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6148/12337074/013c4031019e/tlcr-14-07-2374-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6148/12337074/013c4031019e/tlcr-14-07-2374-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6148/12337074/013c4031019e/tlcr-14-07-2374-f1.jpg

相似文献

1
and co-mutations in resectable non-small cell lung cancer: enduring prognostic value and impaired immunotherapy response.可切除非小细胞肺癌中的共突变：持久的预后价值及受损的免疫治疗反应
Transl Lung Cancer Res. 2025 Jul 31;14(7):2374-2382. doi: 10.21037/tlcr-2025-463. Epub 2025 Jul 22.
2
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.新辅助免疫检查点阻断治疗后，可切除的KRAS突变型肺癌中基于STK11共突变状态的不同临床和免疫结果。
Clin Cancer Res. 2025 Jan 17;31(2):339-351. doi: 10.1158/1078-0432.CCR-24-2983.
3
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.真实世界环境中，存在 STK11 和/或 KEAP1 突变的情况下，KRAS G12C 突变的晚期非小细胞肺癌患者的总生存期。
BMC Cancer. 2023 Apr 17;23(1):352. doi: 10.1186/s12885-023-10778-6.
4
Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.KRAS-TP53共突变对早期非小细胞肺癌患者的预后影响：一项单中心回顾性研究
J Clin Med. 2025 Jul 19;14(14):5135. doi: 10.3390/jcm14145135.
5
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.KRAS、TP53、STK11 和 KEAP1 突变的预后影响及其对免疫治疗 NSCLC 患者 NLR 的影响。
Cancer Treat Res Commun. 2023;37:100767. doi: 10.1016/j.ctarc.2023.100767. Epub 2023 Oct 10.
6
Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.STK11/KRAS 共突变对真实世界泛癌队列免疫治疗反应的影响。
Tumori. 2024 Apr;110(2):146-152. doi: 10.1177/03008916231204441. Epub 2023 Oct 11.
7
A Critical Review of the Prognostic and Predictive Implications of and Mutations and Co-Mutations in Metastatic Non-Small Lung Cancer.转移性非小细胞肺癌中KRAS和NRAS突变及共突变的预后和预测意义的批判性综述
J Pers Med. 2023 Jun 18;13(6):1010. doi: 10.3390/jpm13061010.
8
STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).非小细胞肺癌患者中 STK11 和 KEAP1 突变：西班牙裔人群中的描述性分析和预后价值（STRIKE 登记-CLICaP）。
Lung Cancer. 2022 Aug;170:114-121. doi: 10.1016/j.lungcan.2022.06.010. Epub 2022 Jun 20.
9
Clinical outcomes and immune phenotypes associated with co-occurring mutations in non-small cell lung cancer.与非小细胞肺癌共发突变相关的临床结局和免疫表型
J Thorac Dis. 2022 Jun;14(6):1772-1783. doi: 10.21037/jtd-21-1377.
10
Emerging insights into , and mutations: implications for immunotherapy in patients with advanced non-small cell lung cancer.对、和突变的新见解：对晚期非小细胞肺癌患者免疫治疗的影响。
Transl Lung Cancer Res. 2024 Dec 31;13(12):3718-3730. doi: 10.21037/tlcr-24-552. Epub 2024 Dec 23.

本文引用的文献

1
Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer.一线化疗联合免疫疗法或抗血管生成疗法治疗晚期KRAS突变型非小细胞肺癌的疗效
Transl Oncol. 2025 Mar;53:102317. doi: 10.1016/j.tranon.2025.102317. Epub 2025 Feb 3.
2
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial.KRYSTAL-1试验中接受阿达格拉西布治疗的非小细胞肺癌患者共突变和转录特征的影响
Clin Cancer Res. 2025 Mar 17;31(6):1069-1081. doi: 10.1158/1078-0432.CCR-24-2310.
3
LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer.
在非小细胞肺癌中，LKB1通过Skp2介导的PD-L1蛋白泛素化决定对免疫疗法的敏感性。
J Immunother Cancer. 2024 Dec 18;12(12):e009444. doi: 10.1136/jitc-2024-009444.
4
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.新辅助免疫检查点阻断治疗后，可切除的KRAS突变型肺癌中基于STK11共突变状态的不同临床和免疫结果。
Clin Cancer Res. 2025 Jan 17;31(2):339-351. doi: 10.1158/1078-0432.CCR-24-2983.
5
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.CTLA4 阻断消除了 KEAP1/STK11 相关的对 PD-(L)1 抑制剂的耐药性。
Nature. 2024 Nov;635(8038):462-471. doi: 10.1038/s41586-024-07943-7. Epub 2024 Oct 9.
6
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.评估新辅助免疫检查点阻断在可切除 NSCLC 中的随机对照试验中主要病理缓解和病理完全缓解作为生存替代终点。
J Thorac Oncol. 2024 Jul;19(7):1108-1116. doi: 10.1016/j.jtho.2024.03.010. Epub 2024 Mar 8.
7
Influence of Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in -Mutant Non-Small-Cell Lung Cancer.计算机分析对携带特定突变的非小细胞肺癌中肿瘤免疫微环境及免疫检查点抑制剂临床结局的影响
JCO Precis Oncol. 2024 Feb;8:e2300371. doi: 10.1200/PO.23.00371.
8
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.肺腺癌中 KEAP1 突变促进免疫逃逸和免疫治疗耐药。
Cell Rep. 2023 Nov 28;42(11):113295. doi: 10.1016/j.celrep.2023.113295. Epub 2023 Oct 26.
9
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.帕博利珠单抗用于早期非小细胞肺癌的围手术期治疗。
N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3.
10
The KEAP1-NRF2 pathway: Targets for therapy and role in cancer.KEAP1-NRF2 通路：治疗靶点及在癌症中的作用。
Redox Biol. 2023 Jul;63:102726. doi: 10.1016/j.redox.2023.102726. Epub 2023 Apr 29.